» Articles » PMID: 32801860

Long Non-Coding RNA NEAT1 Promotes the Proliferation, Migration, and Metastasis of Human Breast-Cancer Cells by Inhibiting MiR-146b-5p Expression

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2020 Aug 18
PMID 32801860
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Breast cancer (BC) is the most commonly diagnosed cancer in women. Tumor recurrence and metastasis are the key causes of death in BC patients. Long non-coding RNA (lncRNA) is closely associated with BC progression. lncRNA nuclear-enriched abundant transcript (NEAT)1 has been reported to regulate the proliferation and mobility of several types of cancer cells. However, how lncRNA NEAT1 affects the proliferation and invasion of BC cells is not known.

Methods: Quantitative real time-polymerase chain reaction (qRT-PCR) was used to measure expression of lncRNA NEAT1 and microRNA (miR)-146b-5p in BC tissues and cell lines. Cell Counting Kit (CCK)-8, cell colony-formation, wound-healing, and Transwell™ assays were undertaken to determine the effects of lncRNA NEAT1 and miR-146b-5p on progression of BC cells. The interaction between lncRNA NEAT1 and miR-146b-5p was examined by luciferase reporter, RNA-binding protein immunoprecipitation (RIP), and RNA-pulldown assays.

Results: Expression of lncRNA NEAT1 was upregulated in BC tissues and cell lines. High expression of lncRNA NEAT1 predicted poor overall survival in BC patients. Silencing of expression of lncRNA NEAT1 inhibited epithelial-mesenchymal transition (EMT) and suppressed the proliferation, migration and invasion of BC cells. Ectopic expression of lncRNA NEAT1 induced EMT and promoted BC progression. Mechanistic investigations revealed that miR-146b-5p was a direct target of lncRNA NEAT1, and its expression was correlated negatively with expression of lncRNA NEAT1 in BC tissues.

Conclusion: lncRNA NEAT1 could (i) serve as a novel prognostic marker for BC and (ii) be a potential therapeutic target for BC.

Citing Articles

The association between the expression level of nuclear paraspeckle assembly transcript 1 and the survival rate of head and neck cancer patients after treatment.

Lin N, Hsia S, Vu Nguyen T, Wang T, Sun K, Chiu K J Dent Sci. 2024; 19(4):2074-2081.

PMID: 39347098 PMC: 11437243. DOI: 10.1016/j.jds.2024.05.001.


Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC).

Qattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A Cancers (Basel). 2024; 16(17).

PMID: 39272915 PMC: 11394539. DOI: 10.3390/cancers16173057.


Emerging roles of the long non-coding RNA NEAT1 in gynecologic cancers.

Farzaneh M, Gale Dari M, Anbiyaiee A, Najafi S, Dayer D, Salehi A J Cell Commun Signal. 2023; 17(3):531-547.

PMID: 37310654 PMC: 10409959. DOI: 10.1007/s12079-023-00746-x.


Clinical significance of long non-coding RNA ZEB2-AS1 and EMT-related markers in ductal and lobular breast cancer.

Zarei M, Malekzadeh K, Omidi M, Mousavi P Cancer Rep (Hoboken). 2023; 6(5):e1826.

PMID: 37088469 PMC: 10172159. DOI: 10.1002/cnr2.1826.


Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance.

Kashyap D, Sharma R, Goel N, Buttar H, Garg V, Pal D Front Genet. 2023; 13:993687.

PMID: 36685962 PMC: 9852779. DOI: 10.3389/fgene.2022.993687.


References
1.
Xu J, Wang Z, Li S, Chen J, Zhang J, Jiang C . Combinatorial epigenetic regulation of non-coding RNAs has profound effects on oncogenic pathways in breast cancer subtypes. Brief Bioinform. 2016; 19(1):52-64. DOI: 10.1093/bib/bbw099. View

2.
Wu Y, Yang L, Zhao J, Li C, Nie J, Liu F . Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer. Mol Cancer. 2015; 14:191. PMC: 4640217. DOI: 10.1186/s12943-015-0455-5. View

3.
Lourenco A, Roukens M, Seinstra D, Frederiks C, Pals C, Vervoort S . C/EBPɑ is crucial determinant of epithelial maintenance by preventing epithelial-to-mesenchymal transition. Nat Commun. 2020; 11(1):785. PMC: 7005738. DOI: 10.1038/s41467-020-14556-x. View

4.
Yeo S, Guan J . Breast Cancer: Multiple Subtypes within a Tumor?. Trends Cancer. 2017; 3(11):753-760. PMC: 5802368. DOI: 10.1016/j.trecan.2017.09.001. View

5.
Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View